Shares of SkinBioTherapeutics plc (LON:SBTX – Get Free Report) dropped 10.4% during mid-day trading on Friday . The company traded as low as GBX 7.55 and last traded at GBX 7.84. 830,164 shares traded hands during trading, a decline of 65% from the average session volume of 2,352,551 shares. The stock had previously closed at GBX 8.75.
SkinBioTherapeutics Price Performance
The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01. The stock has a market cap of £20.32 million, a price-to-earnings ratio of -49.00 and a beta of 0.10. The business’s 50-day simple moving average is GBX 10.19 and its two-hundred day simple moving average is GBX 9.97.
About SkinBioTherapeutics
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
Further Reading
- Five stocks we like better than SkinBioTherapeutics
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
